Olympus Optical Company, Ltd.

Olympus Corporation

Agency of Industrial Science and Technology

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Pharma Corporation

Hiroyuki Irie

Yasuharu Hakamatsuka

Masami Miura

Masaaki Hirose

Taeko Miwa

Shinobu Kuwae

Kenmi Miyano

Wataru Otani

Hideyuki Ohi

Motohiro Toriyama

Sukezo Kawamura

Hikaru Inoue

Hiroshi Fukuda

Takahiro Suzuki

Hiroki Hibino

Hitoshi Mizuno

Yoshiharu Saito

Yukari Kawamoto

Gen Horie

Hideki Koyanagi

Yoshiyuki Yokokawa

Shin Katayama

A protein participating in the addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genus; a gene coding this protein; a mutant of this gene; a vector carrying the mutant gene; a yeast strain belonging to the genushaving been transformed by this vector; a process for producing a protein with reduction of an acidic sugar chain by using the transformed yeast strain; and a glycoprotein thus produced, are described.

Process for producing protein with reduction of acidic sugar chain and glycoprotein produced thereby

The present invention discloses a cell culturing system that cultures predetermined cells collected from a patient and supplies cultured cells to the original patient, which together with enabling correlations between the cultured cells and the supplier of the cells to be managed accurately and easily at all times, allows cultured cells and patients to be collated rapidly.

Cell culture system apparatus for checking cultured cells and apparatus for culturing cells

A gene participating in addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genusis described. Also described is a means of suppressing a functional product encoded by the gene.

The present invention intends to find out a gene participating in addition of mannose phosphate to a sugar chain of a glycoprotein originating in a yeast belonging to the genusand provide a means of controlling the same. The present invention also intends to provide a process for producing a protein with reduction of an acidic sugar chain by using the thus controlled yeast strain belonging to the genus. Namely, the present invention includes a protein participating in the addition of mannose phosphate to a sugar chain of a glycoprotein; a gene encoding this protein; a mutant of this gene; a vector carrying the mutant gene; a yeast strain belonging to the genushaving been transformed by this vector; a process for producing a protein with reduction of an acidic sugar chain by using the transformed yeast strain; and a glycoprotein thus produced.

An artificial bone comprising a calcium phosphate-based ceramic porous body having a plurality of pores which are three-dimensionally distributed throughout an entire region of the porous body including a surface thereof and have a diameter ranging from 0.01 &#x3bc;m to 2000 &#x3bc;m, and interconnecting portions which are formed between neighboring pores, interconnect a plurality of pores existing on a surface of the porous body.

Artificial bone and tissue engineering carrier

Hollow porous ceramic carrier for embedding in patient for sustained medicament release and method of preparation thereof

A plasminogen activator such as urokinase or tissue plasminogen activator is covalently bonded to a porous body composed of calcium phosphate to form a plasminogen activator-porous body complex. The tricalcium phosphate can be .alpha.-tricalcium phosphate, .beta.-tricalcium phosphate, hydroxyapatite, tetracalcium phosphate, octacalcium phosphate and mixtures thereof. In a preferred embodiment, .beta.-tricalcium phosphate which has excellent biocompatibility with the body or a mixture of .beta.-tricalcium phosphate and hydroxyapatite is used. Preferably, synthetic calcium phosphate is used is to avoid impurities contained by natural calcium phosphate. Covalent bonding is by crosslinking with glutaraldehyde, bismaleimides, dihalogenic aryls or diisocyanates, or by using cyanogen bromide, diazotization or periodic acid. The complex can be filled into a column to form a bioreactor. A granular complex can be intravascularly injected into the blood of a patient to provide thrombotic activity for a long period of time. In another embodiment, a complex of a predetermined shape can be implanted to provide thrombotic activity.

Plasminogen activator covalently bonded to a porous body of

Powdery calcium carbonate and a powdery dihydrate of calcium monohydrogenohosphate are weighed to get a Ca/P ratio of 1.45 to 1.67. The powdery mixture thus prepared is then added pure water at a temperature of 30.degree. C. or higher to obtain an aqueous slurry having a concentration of about 10% by weight. Thereafter, the aqueous slurry is subjected to a rotational attrition by using a ball mill to conduct a mechanochemical reaction of the calcium carbonate with the dihydrate of calcium monohydrogenphosphate. The slurry is then dried completely at 80.degree. C., followed by pulverization to yield a dry powder of calcium phosphate hydrate. The dry powder is calcinated at a temperature ranging from 720.degree. to 1,150.degree. C. for 1-10 hours or more to give calcium phosphate powder, which is molded in a desired shape and is sintered at a certain temperature to obtain a sintered body of calcium phosphate. The calcium phosphate and the sintered body thereof, thus prepared, have an assured biological safety in that the calcium phosphate is free from hemolysis, antigenicity and cytotoxicity.

Method of preparing calcium phosphate

A drug-impregnated ceramic to be embedded in a living body is disclosed, and includes a porous ceramic having pores with a pore size of 10 to 300 .mu.m, a drug impregnating the porous ceramic via the pores, and a surface layer for controlling the release of the drug. The surface layer is formed to cover at least a portion of the outer surface of the porous ceramic and has a porosity lower than that of the porous ceramic.

Drug-impregnated ceramic

A sustained release material to be buried at a position close to a diseased part in a living body to slowly release an impregnated liquid drug includes a core mainly consisting of a ceramic material and having a plurality of pores formed at a predetermined porosity, and a surface layer mainly consisting of a ceramic material, formed around the outer surface of the core, and having a plurality of pores having a pore size or porosity smaller than that of the pores formed in the core.

Sustained release material and method of manufacturing the same

A prosthetic artificial bone having a double-layered structure obtained by forming a high porosity portion having a porosity of from 40 to 90% and a lower porosity portion having a porosity of 50% or less, into an integral body, and wherein the high porosity portion and the lower porosity portion each comprise a ceramics containing calcium and phosphorus.

Prosthetic artificial bone having ceramic layers of different porosity

A ceramic member for a living body includes a first end portion formed of a material having affinity with a living body and consisting of a dense material, and a second end portion formed of a material having affinity with a living body and consisting of a porous material. A method of manufacturing a ceramic member for a living body, includes the steps of mixing a ceramic powder having affinity with a living body, water, and a binder to prepare a dense material slurry, mixing a ceramic powder having affinity with a living body, water, a binder, and a foaming agent to prepare a porous material slurry, injecting, in order to form a two-layered base material consisting of the dense material slurry and the porous material slurry, the dense material slurry and the porous material slurry obtained in the two steps in a mold such that the dense and porous material slurries are not mixed with each other, and drying the base material, and after the drying step, heating the base material at a predetermined rate, and sintering the base material at a predetermined temperature.

Growing community of inventors

Tokyo, Japan

Hiroyuki Irie